Compounds and methods for treating cancer

US11325892B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11325892-B2
Application numberUS-201916422519-A
CountryUS
Kind codeB2
Filing dateMay 24, 2019
Priority dateAug 7, 2014
Publication dateMay 10, 2022
Grant dateMay 10, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound according to Formula (II): or a pharmaceutically acceptable salt thereof, wherein R 1 is halo; X is —(C═O)NR 4 —; Y is and R 2 , R 3 , and R 4 are each independently H or an unsubstituted C 1-6 alkyl. 2. The compound of claim 1 , wherein the compound according to Formula (II) has the structure of Formula (IIa): or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein R 1 is Cl. 4. The compound of claim 1 , wherein R 4 is H. 5. The compound of claim 1 , wherein R 2 is H and R 3 is CH 3 . 6. The compound of claim 1 , wherein the compound according to Formula (II) is or a pharmaceutically acceptable salt thereof. 7. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , and a pharmaceutically acceptable carrier.

Assignees

Inventors

Classifications

  • attached in position 2 or 6 · CPC title

  • Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

  • having a hetero atom as the second substituent in position 4 · CPC title

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

  • from aromatic carboxylic acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11325892B2 cover?
This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell c…
Who is the assignee on this patent?
Mayo Found Medical Education & Res
What technology area does this patent fall under?
Primary CPC classification C07D295/192. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).